重组腺病毒Canstatin对人肝癌HepG2细胞增殖影响的研究

为研究重组腺病毒Canstatin感染人肝癌HepG2细胞及细胞转染后Canstatin在HepG2细胞中的表达,探讨Canstatin基因对人肝癌HepG2细胞生长增殖的影响。采用不同感染复数(MOI=10、40、80)的腺病毒Ad-Canstatin-GFP感染HepG2细胞,倒置荧光显微镜下观察细胞形态,流式检测感染效率,Real-Time PCR和Western blot法检测HepG2细胞中Canstatin mRNA和蛋白表达。CCK-8法检测细胞增殖能力的变化,Western blot法检测细胞中PCNA蛋白的表达。结果显示MOI为40时,72 h感染率可达到98.9%,HepG2细胞中Canstatin mRNA和蛋白表达均高于对照组和空载体组(P0.05)。HepG2细胞感染Ad-Canstatin腺病毒后生长增殖受到抑制(P0.05),且PCNA的表达低于对照组(P0.05)。由此可知,Canstatin抑制人肝癌HepG2细胞的生长增殖有作用可能与影响PCNA的表达有关。     

子宫内膜癌中血管生成拟态的临床意义

目的研究人子宫内膜癌组织中是否存在血管生成拟态（VM）及其临床意义。方法收集子宫内膜癌标本60例及临床病理资料,CD34-PAS双重染色证实VM存在,分析VM与患者临床病理指标之间的关系。结果13例标本中存在VM。低分化子宫内膜癌中VM出现的机率高于高分化子宫内膜癌（P=0．001）。VM组的手术病理分期比无VM组高（P=0．013）。VM组有更高的转移率（P=0．003）。结论子宫内膜癌组中存在VM,是高度恶性生物学行为的基础之一。     

1例肝癌患者非癌肝组织的病理分析

对６１例肝癌患者的非癌肝组织进行了病理观察和分析。结果表明：３４例伴有肝硬化,２７例无肝硬化。３４例肝硬化中,活动性肝硬化３２例（占９４１％）,２例静止性肝硬化中仍可见单个和灶性肝细胞坏死。２７例无肝硬化患者中,呈慢性活动性肝炎表现者２６例（占９６３％）,１例为慢性迁延性肝炎。由此提示：肝癌的临床发展中,既存在慢性肝炎—肝硬化—肝癌的三个阶段,也存在慢性肝炎—肝癌的两个阶段过程。积极治疗肝炎,阻止肝细胞坏死也是预防肝癌的重要手段之一。     

CyclinB1、Cdk1、PCNA和Ki-67在食管癌组织中的表达

探讨食管癌组织中CyclinB1、Cdk1、PCNA和Ki-67的表达及其临床病理学意义．采用免疫组织化学SABC法,检测CyclinB1、Cdk1、PCNA和Ki-67在食管癌组织细胞中的表达．CyclinB1和Cdk1染色定位于细胞浆和细胞核．PCNA和Ki-67染色定位于细胞核．在所研究的食管癌病例中,CyclinB1阳性表达的病例占92．9％,Cdk1阳性表达的病例占78．6％,100％的病例均呈PCNA和Ki-67阳性表达．CyclinB1、Cdk1、PCNA和Ki-67在食管癌组织中均出现高频率的表达．CyclinB1、Cdk1、PCNA和Ki-67的阳性表达率及表达强度同食管癌分化程度有密切的关系．     

饮用咖啡与胰腺癌患病的Meta分析

目的 综合评价饮用咖啡因素与胰腺癌发生的相关性,进一步探讨胰腺癌的危险因素.方法 检索1970.01.01/2010.10.01国内外公开发表的有关人群饮用咖啡和胰腺癌发生的病例对照研究,制定纳入标准,采用Rev Man4.2软件对研究资料进行Meta分析,定量综合评价饮用咖啡与胰腺癌的关系.结果 共有15组病例-对照研究符合入选标准,累积胰腺癌病例共3 335例和正常对照者共15 064例.Meta分析显示,合并OR=1.08(95％ CI:0.88～1.31),(P=0.48),差异无统计学意义;男性组结果显示,OR和95％ CI为1.14(0.95-1.37),差距不具有统计学意义(P=0.15),女性组结果显示OR和95％CI为1.18(0.98-1.43),(P=0.09),由于P＜0.1,故属于边缘性显著差异.结论 女性胰腺癌患者中有饮用咖啡习惯与无饮用咖啡习惯的人相比,饮用咖啡的习惯可能会增加胰腺癌的发病风险.     

Preoperative diagnosis of hepatocellular carcinoma patients with bile duct tumor thrombus using deep learning method

Preoperative diagnosis of bile duct tumor thrombus (BDTT) is clinically important as the surgical prognosis of hepatocellular carcinoma (HCC) patients with BDTT is significantly different from that of patients without BDTT. Although dilated bile ducts (DBDs) can act as biomarkers for diagnosing BDTT, it is easy for doctors to ignore DBDs when reporting the imaging scan result, leading to a high missed diagnosis rate in practice. This study aims to develop an artificial intelligence (AI) pipeline for automatically diagnosing HCC patients with BDTT using medical images. The proposed AI pipeline includes two stages. First, the object detection neural network Faster R-CNN was adopted to identify DBDs; then, an HCC patient was diagnosed with BDTT if the proportion of images with at least one identified DBD exceeded some threshold value. Based on 2354 CT images collected from 32 HCC patients (16 with BDTT and 16 without BDTT, 1∶1 matched), the proposed AI pipeline achieves an average true positive rate of 0.92 for identifying DBDs per patient and a patient-level true positive rate of 0.81 for diagnosing BDTT. The AUC value of the patient-level diagnosis of BDTT is 0.94 (95% CI: 0.87, 1.00), compared with 0.71 (95% CI: 0.51, 0.90) achieved by random forest based on preoperative clinical variables. The high accuracies demonstrate that the proposed AI pipeline is successful in the diagnosis and localization of BDTT using CT images.     

复方肿瘤血管生成抑制因子口服液与化疗药物合用对小鼠Ehrlich腹水癌的抑制作用研究

本文研究了复方肿瘤血管生成抑制因子口服液（ＣＯＬ－ＴＡＩ）与化疗药物合用对小鼠Ｅｈｒｌｉｃｈ腹水癌的抑制作用,结果表明,单独服用ＣＯＬ－ＴＡＩ的各实验组生命延长率均大于对照组;单独使用环磷酰胺（ＣＴＸ）或阿霉素（ＡＤＭ）时,生命延长率分别为３６．９８％和１１９．６７％,二者分别与ＣＯＬ－ＴＡＩ合用时,生命延长率分别为７９．６４％和１５２．５０％,由此可见,ＣＯＬ－ＴＡＩ与化疗药物合用有显著协同抑制Ｅｈｒｌｉｃｈ腹水癌生长和延长存活时间的作用．     

内镜微波凝固治疗食管癌的有效性和安全限度

目的：探讨内镜微波凝固治疗晚期食管癌的有效性和安全限度。方法：选择晚期食管癌病人１０例,经电视内窥镜行微波凝固治疗,控制微波工作电流１１０￣１２０ｍＡ,输出时间〈１５ｓ,５￣７ｄ后手术切除癌肿,标本通过光镜和电镜检查。结果：经微波凝固治疗患者进食情况改善,取得满意的姑息性治疗效果。微波除对突入腔内癌瘤凝固气化外,仍对食管壁肿瘤组织产生杀伤,深度达４ｎｍ。结论：内镜微波凝固治疗晚期食管癌是安全有效的     

Serum amyloid A: An acute-phase protein involved in tumour pathogenesis

The synthesis of acute-phase protein serum amyloid A (SAA) is largely regulated by inflammation- associated cytokines and a high concentration of circulating SAA may represent an ideal marker for acute and chronic inflammatory diseases. However, SAA is also synthesized in extrahepatic tissues, e.g. human carcinoma metastases and cancer cell lines. An increasing body of in vitro data supports the concept of involvement of SAA in carcinogenesis and neoplastic diseases. Accumulating evidence suggests that SAA might be included in a group of biomarkers to detect a pattern of physiological events that reflect the growth of malignancy and host response. This review is meant to provide a broad overview of the many ways that SAA could contribute to tumour development, and accelerate tumour progression and metastasis, and to gain a better understanding of this acute-phase reactant as a possible link between chronic inflammation and neoplasia. Received 11 June 2008; received after revision 10 July 2008; accepted 28 July 2008